Type 2 Diabetes Medicines Partnership
Smarter, faster, responsive guidance for type 2 diabetes
A global partnership advancing real-time evidence for better diabetes care worldwide. While the program is currently paused, its outputs continue to inform clinical guidelines and global research.
Challenge
Racing to treat a growing global disease
Diabetes affects over 500 million people worldwide, contributing to tens of millions of deaths and disabilities each year. The burden is greatest in low- and middle-income countries, where prevalence is rising fastest.
New treatments are constantly emerging, but the pace of research makes it difficult to keep clinical guidance timely, trustworthy, and responsive – especially in resource-limited settings.
The Type 2 Diabetes Medicines Partnership tackled this challenge by creating a living evidence framework to rapidly translate emerging research into actionable guidance for frontline care.
Approach
Fast, rigorous, and accessible guidance
In collaboration with global partners, we developed a living evidence system that rapidly synthesised new research into high-quality recommendations for type 2 diabetes treatment.
Our main output was a living database of randomized trials – containing over 850 studies – built on inclusion and exclusion criteria co-developed with partners.
Our framework supported:
Monthly surveillance of global clinical trials
Biannual network meta-analyses (NMAs) comparing drug effectiveness
GRADE assessments to evaluate certainty of evidence
Risk-stratified absolute effect estimates for personalized care
Tools to help guideline developers translate evidence into practice
Learning Forum
Watch “Standards and Best Practices for Maintaining Living Evidence.”
Impact
Transforming diabetes care with continually updated guidance and frontline decision tools
Our dataset is regularly updated with the latest, most rigorous research in treatment for type 2 diabetes. Although the partnership is on pause, we continue to collaborate with MAGIC to publish updated guidance and frontline tools that optimise clinical care.
Explore our recent publications and tools
Guiding Practice
August 2025
Our latest living clinical practice guidelines are featured in BMJ Rapid Recommendations.
Cardiovascular, kidney related, and weight loss effects of therapeutics for type 2 diabetes: a living clinical practice guideline
BMJ 2025; 390, 14 August 2025
Supporting frontline care
MATCH-IT
An interactive, multiple comparisons decision tool summarising results across multiple interventions and outcomes.
Leading Global Research
August 2025
Our living systematic review and network meta-analysis synthesises 869 trials and links to practice guidelines and tools.
Medications for adults with type 2 diabetes: a living systematic review and network meta-analysis
BMJ 2025; 390, 14 August 2025
Reach out to Britta Jeppesen, Chief Scientist at Alive, at hello@aliveevidence.org, to learn more.
Partners
Leaders in research, tech, policy, and philanthropy
This partnership united researchers, clinicians, and evidence experts from around the world to build a living evidence framework, reduce research waste, and accelerate impact.
The ALIVE DIFFERENCE
Get in touch
Even while paused, the system’s outputs continue to support decision-making for type 2 diabetes around the world. Reach out to Britta Jeppesen, Chief Scientist at Alive, at hello@aliveevidence.org, to learn more.
Alive Newsletter
Stay connected to Alive
Quick Links
Home
About Us
What we do
Partnerships
HPV Living Evidence
DESTINY for Improvements in Climate & Health
Type 2 Diabetes Medicines
Learning Forum
Contact Us
hello@aliveevidence.com
